Clinical Trial Comparing Standard Wound Closure Techniques Versus TissuGlu® Surgical Adhesive

December 3, 2013 updated by: Cohera Medical, Inc.

A Clinical Investigation for a Randomized Study Comparing Standard Wound Closure Technique With Drains (Control) to Standard Wound Closure Techniques Plus TissuGlu® and No Drains (Test) During Abdominoplasty

The purpose of this study is to determine if TissuGlu® Surgical Adhesive is safe and effective alternative to drains(standard of care) for fluid management following abdominoplasty. It is hypothesized that the use of the Cohera device will facilitate reduction or closure of dead space when applied to planar surfaces created during an abdominoplasty procedure.

Study Overview

Detailed Description

The Cohera TissuGlu® study is a pivotal, prospective clinical investigation for a randomized, controlled, multicenter non-inferiority study comparing standard wound closure technique with drains (control) to standard wound closure techniques plus TissuGlu® and no drains (test) during abdominoplasty. TissuGlu® will be applied to the test group prior to standard closure of the abdominal flap thereby eliminating the deadspace between the fascia and the flap. No closed suction drains will be inserted in the test group. The control group will receive closed suction drains per the standard of care. It is hypothesized that the elimination of deadspace in the wound in the test group will prevent post-surgical fluid from developing and causing seroma and that the number of invasive treatments related to aspirations in the test group will not be inferior to the management and removal of drains and aspirations for seroma in the control group. The study will be conducted with 130 patients (65 test, 65 control) at up to 5 sites.

Study Type

Interventional

Enrollment (Actual)

130

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • North Carolina
      • Huntersville, North Carolina, United States, 28078
        • The Hunstad Kortesis Center for Cosmetic Plastic Surgery and MedSpa

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female, ≥ 18 years of age
  • Provide signed and dated informed consent form
  • Willing to comply with all study procedures, schedules and be available for the follow-up evaluations for the duration of the study
  • Willing to follow instructions for incision and drain care, and follow guidelines related to resumption of daily activities
  • Agree not to schedule any additional elective surgical procedures that involve an incision until their participation in the study is complete
  • In good general health in the opinion of the Investigator with no conditions that would significantly impact wound healing as determined by medical history, and review of recent concomitant medications
  • Requiring at least one full thickness surgical incision of at least 20cm in length as part of elective abdominoplasty
  • ≤ ASA2 - American Society of Anesthesiologists Physical Classification System (2=subject with mild systemic disease)
  • Have a Body Mass Index (BMI) ≤ 28

Exclusion Criteria:

  • Pregnancy or lactation
  • Previous abdominoplasty
  • Prior bariatric or weight loss surgery
  • Lost ≥ 15% of maximum lifetime bodyweight (excluding pregnancy weight gain)
  • Known medical condition that results in compromised blood supply to tissues
  • Have known or suspected allergy or sensitivity to any test materials or reagents
  • Have severe co-morbid conditions (e.g., heart disease)
  • Are currently a smoker or have smoked within 30 days of prescreening as determined by nicotine test
  • Any condition known to effect wound healing, such as collagen vascular disease
  • Be known to have a blood clotting disorder and/or be willing to discontinue anti-coagulation therapy including aspirin
  • Diagnosis of diabetes with current medical treatment
  • Receiving antibiotic therapy for pre-existing condition or infection
  • Have known personal or family history of keloid formation or hypertrophic scarring
  • Currently taking systemic steroids or immunosuppressive agents
  • Undergoing concurrent adjacent or congruent Liposuction agents
  • Use of pain pumps after the abdominoplasty procedure
  • Concurrent use of fibrin sealants or other internal wound care devices
  • Concurrent hernia repair greater than 6 cm and/or requiring the use of mesh
  • Mini abdominoplasty (abdominoplasty without umbilical transposition)
  • Be participating in any current clinical trial or have participated in any clinical trial within 30 days of enrollment in this study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: TissuGlu Surgical Adhesive
Standard wound closure techniques plus TissuGlu and no drains.
Standard Wound Closure Techniques Plus TissuGlu and no drains.
No Intervention: Control - Standard of Care
Standard wound closure techniques with drains.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Post-Operative Invasive Treatments
Time Frame: 90 Days

Number of Post-Operative Invasive Treatments, where Invasive Treatment is defined as one of the following events:

  • Removal of an in-dwelling drain;
  • Needle aspiration to remove fluid from a clinically-diagnosed palpable seroma;
  • Invasive action to the drain or drain wound such as repositioning or re-attaching the drain retention sutures;
  • Reinsertion of a drain
90 Days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Secondary Outcome Measures
Time Frame: 90 Day
• Cumulative drain volume, aspiration volume, and total wound drainage (drain volume + aspiration volume)
90 Day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Joseph Hunstad, MD, The Hunstad Kortesis Center for Cosmetic Plastic Surgery and MedSpa

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2013

Primary Completion (Actual)

September 1, 2013

Study Completion (Actual)

November 1, 2013

Study Registration Dates

First Submitted

December 6, 2012

First Submitted That Met QC Criteria

February 12, 2013

First Posted (Estimate)

February 15, 2013

Study Record Updates

Last Update Posted (Estimate)

December 5, 2013

Last Update Submitted That Met QC Criteria

December 3, 2013

Last Verified

December 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PRO-100-0085

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Disorder of Skin and/or Subcutaneous Tissue of Trunk

Clinical Trials on TissuGlu Surgical Adhesive

3
Subscribe